Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC)
Authors
Skoulidis, F.De Langen, A.
Paz-Ares, L. G.
Mountzios, G. S.
Curioni-Fontecedro, A.
Couraud, S.
Janssens, A.
Rocco, D.
Ohashi, K.
Vincent, M. D.
Kang, J. H.
Schvartsman, G.
Lindsay, Colin R
O'Byrne, K. J.
Dziadziuszko, R.
Andersen, J. A. L.
Hindoyan, A.
Wilmanski, T.
Wang, Y.
Schuler, M. H.
Affiliation
University of Texas MD Anderson Cancer Center, Houston, TXIssue Date
2023
Metadata
Show full item recordCitation
Skoulidis F, De Langen A, Paz-Ares LG, Mountzios GS, Curioni-Fontecedro A, Couraud S, et al. Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003679.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.9008Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9008Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.9008